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Abstract
The objectives of this report are to determine the association between performance-based 
measures of physical function with caregiver reports of physical function in older adults with 
Alzheimer’s disease (AD) and to examine whether those associations vary by the level of patients’ 
cognitive functioning.
Subjects included 180 patient-caregiver dyads who are enrolled in a clinical trial testing the impact 
of an occupational therapy intervention plus guideline-level care to delay functional decline among 
older adults with Alzheimer’s disease. The primary caregiver-reported measure is the Alzheimer’s 
Disease Cooperative Study Group Activities of Daily Living Inventory (ADCS-ADL). 
Performance-based measures include the Short Physical Performance Battery (SPPB) and the 
Short Portable Sarcopenia Measure (SPSM).
Analysis of covariance (ANCOVA) models were used to determine the associations of each 
physical performance measure with ADCS-ADL, adjusting for cognition function and other 
covariates.
We found significant correlations between caregiver-reports and observed performance-based 
measures across all levels of cognitive function, with patients in the lowest cognitive group 
showing the highest correlation. These findings support the use of proxy reports to assess physical 
function among older adults with AD.
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Introduction
The number of worldwide cases of Alzheimer disease (AD) and related dementias is 
growing as the population ages; an estimated 22% of the world’s population will have 
dementia by the year 2050.1 There is currently no cure for AD and over a period of 5–10 
years, the condition typically results in severe functional and cognitive disability. Previous 
studies specifically targeting physical decline have provided evidence that physical function 
can be improved among older adults with dementia.2,3 In a prior clinical trial, we previously 
reported that a collaborative care program for older adults with AD could improve 
behavioral symptoms, but this program did not slow the progression of physical decline.4
Previous studies have compared self-report as compared to performance-based measures of 
physical function in older adults, but not in the context of persons with AD and their 
caregivers.5–8 We are currently conducting the Alzheimer’s Disease Multiple Intervention 
Trial (ADMIT) which seeks to delay functional decline in AD patients.9 This study is unique 
in that the outcomes include two different performance-based measures of physical function, 
the Short Performance Physical Battery (SPPB) and Short Portable Sarcopenia Measure 
(SPSM) as well as a caregiver reported measure of function. The objective of this report is to 
determine the association of these performance-based measures with caregiver assessments 
of patients’ physical function and to examine whether those associations vary by the level of 
the patients’ cognitive functioning in a cohort of older adults with AD.
Methods
Data for this report were collected from baseline assessments of all subjects in the ADMIT 
trial.9 A complete description of the ADMIT protocol has been previously published.9 
Briefly, ADMIT is a randomized single blind controlled clinical trial with a parallel design 
and a 1:1 allocation ratio comparing the effectiveness of a two-year home-based 
occupational therapy intervention to enhanced usual care in preventing physical decline 
among older adults with AD.9 Subjects were enrolled from the Healthy Aging Brain Center 
and its related clinical programs at Eskenazi Health in Indianapolis, Indiana.10–14 Patients 
were eligible if they met diagnostic criteria for possible or probable Alzheimer’s disease as 
determined by the physicians in this memory care practice. All patients in this practice 
complete formal neuropsychological testing and clinical assessments adapted from the 
CERAD battery of tests.9 Other inclusion criteria included community-dwelling, English-
speaking patients who were aged 45 years and older who had an eligible caregiver willing to 
participate in the study. The caregiver was eligible if he or she was 18 years old, English 
speaking, and had regular access to a telephone. Following informed consent of both patients 
and their caregivers, a team of professional research assistants completed an in-home 
baseline assessment (described below). Following the baseline in-home assessment, dyads 
were randomized to the control or intervention group. Prior to enrollment, study procedures 
were approved by the institutional review board of Indiana University/ Purdue University 
Indianapolis.
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Instruments
The primary caregiver-reported measure is the Alzheimer’s Disease Cooperative Study 
Group Activities of Daily Living Inventory (ADCS-ADL).15 This is a 23-item inventory 
developed by the ADCS Group that is administered to the patient’s caregiver by trained 
research staff. The caregiver is asked to focus on the patient’s performance over the past 
month. Notably, the caregiver reports on what the patient actually did rather than an 
assessment of what the patient might be able to do. The inventory assesses the traditional 
activities of daily living (e.g., bathing) as well as variations on instrumental activities of 
daily living (e.g., using the telephone). 15 Scores vary from 0 to 78 with higher scores 
indicating greater levels of function.
Patient’s cognitive function was measured by the Mini Mental Status Examination (MMSE), 
a 30 point scale, with lower scores indicating increased cognitive impairment.16 We use the 
MMSE is this study for three reasons. First, scores on the MMSE allow other researchers to 
compare our study sample with previously reported study samples with dementia on this 
commonly used measure of cognitive function. Second, we sought to examine whether 
subjects with poorer cognitive function as measured by the MMSE would be able to 
understand the examiner instructions to properly complete performance-based measures. 
Third, we use the MMSE score to determine if the correlations between proxy-reported and 
performance-based measures deteriorate as cognitive function worsens.
Physical performance measures include the Short Physical Performance Battery (SPPB) and 
the Short Portable Sarcopenia Measure (SPSM). The SPPB is a standardized measure of 
lower extremity physical performance that includes walking, balance, and power tasks. It has 
been used in a broad range of epidemiological studies of aging.17–20 This scale has proven 
reliable and valid for predicting disability, nursing home placement, hospital admission, and 
mortality.8,20–23 The SPPB score is based on timed measures of standing balance, walking 
speed, and repeated chair rises, each of which is scored 0 to 4 based on standardized criteria. 
Total scores vary from 0 to 12, with higher scores indicating better function. The SPSM was 
conceptualized as a measure of sarcopenia that combines muscle quantity and function.24 
The SPSM can be used to follow change in muscle status over time with each person as his 
or her own control. The scale is based on timed chair rises, body mass index, and grip 
strength. Scores vary from 0 to 18, with higher scores indicating less sarcopenia. Patients 
only received total scores on the SPPB and SPSM if they received a score for each item 
within the scale. Performance tasks that were refused were not scorable. Patients who were 
unable or unsafe to stand on a scale did not receive a score for SPSM.
Analyses
Descriptive statistics including mean, standard deviation, and range for continuous variables 
and frequency and percent in each category for categorical variables were calculated. 
Analysis of variance (ANOVA) models and chi-square tests were used to compare baseline 
characteristics across the MMSE quartiles. Pearson correlation coefficients and their p-
values were calculated for the associations of the two performance-based measured with the 
ADCS-ADL. Analysis of covariance (ANCOVA) was used to identify baseline 
characteristics significantly associated with the ADCS-ADL. These baseline characteristics 
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are shown in Table 1 but only significant variables are shown in Table 2. The two physical 
performance measures were each regressed against ADCS-ADL in analyses adjusting for 
these same covariates. Stepwise and backwards selection methods were used to identify final 
separate parsimonious models for the ADCS-ADL scores including covariates significant at 
the alpha=0.05 level. Standardized regression coefficients were shown from the models 
where one standard deviation increase on the independent variable indicates the change in 
standard deviations of the dependent variable. Interactions between the covariates with 
SPSM or SPPB were investigated and included if significant at the alpha=0.05 level. If the 
final model included significant interactions, partial correlation coefficients were also 
calculated after stratifying by that covariate.
Results
One-hundred eighty patient-caregiver dyads were enrolled in the study between March 2011 
and October 2013; 91 (50.6%) were randomized to receive the occupational therapy 
intervention. Of the total enrolled patients, 175 had ADCS-ADL scores, 174 patients had 
SPPB scores, 144 had SPSM scores, and 179 had MMSE scores. The final study sample was 
composed of the 168 patients with completed ADCS-ADL, SPPB and MMSE scores.
Table 1 shows the baseline characteristics of patients and caregivers both overall and 
stratified by quartiles based upon MMSE scores. Among all patients, 69% were women and 
42% were white. The mean (SD) age was 78 (9) years with a range from 53–102 and a 
median of 79. Only 24% had attained education beyond high school. Mean ADCS-ADL and 
MMSE scores are consistent with other clinical trials reported in the literature among older 
adults with AD.25,26 There were 164 caregivers for the 168 patients; 160 caregivers cared for 
one patient and 4 cared for 2 patients each. There were no differences in patient or caregiver 
demographic characteristics or SPSM scores across the MMSE quartiles (p>0.05 for all). 
However, ADCS-ADL and SPPB scores differed significantly according to MMSE levels. In 
particular, those in the highest MMSE quartile had significantly better ADCS-ADL scores 
than those in all other quartiles (p<0.05) and higher SPPB scores than those in the lowest 
two quartiles (p<0.05).
Figure 1 shows scatter plots and regression lines between each of the performance-based 
physical function measures with the ADCS-ADL total. SPPB was highly correlated with the 
ADCS-ADL (r=0.52, p<0.0001). SPSM was modestly but significantly correlated with the 
ADCS-ADL (r=0.20, p=0.0202).
The standardized Cronbach coefficient alpha was 0.77 for the SPPB and 0.42 for the SPSM. 
Results on the SPPB were comparable to established internal consistency of 0.76.8. There 
are no published results on the internal consistency of SPSM. However, given that there are 
only three items in the SPSM, it is possible that Cronbach alpha underestimates its internal 
consistency. We were encouraged that we did not find floor or ceiling effects with the SPPB 
in this patient population although there may be a slight floor effect for the SPSM. The 
range for the SPSM is 0–14.5 with a mean of 3.9 and a standard deviation of 3.6. The range 
for the SPPB was 0–11 with a mean of 4.2 and a standard deviation of 3.0. There were 28 
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patients (20.6%) who scored a 0 on the SPSM and 10 (6.0%) who scored 0 on the SPPB. 
The correlation between the SPSM and SPPB was 0.35 (p<0.0001; n=136).
Table 2 shows the results from the ANCOVA models on the association between the 
reported measure (ADCS-ADL) and performance-based measures (SPPB and SPSM) 
including significant interactions. We found a significant interaction between SPPB and the 
MMSE quartiles (p=0.0241) in the model on ADCS-ADL, indicating significant differences 
in the correlations between SPPB and ADCS-ADL across MMSE quartiles. In fact, the 
partial correlation coefficient was significantly higher for patients in the lowest MMSE 
quartile group (ρ=0.65, p=0.0043) when compared to patients in the highest MMSE quartile 
group (ρ=0.43). While spousal caregiver relationship was associated with lower ADCS-ADL 
scores, this relationship had no impact on the correlation between SPPB and ADCS-ADL.
Looking at the models using SPSM, a significant interaction between age group 
(dichotomized at the median) and SPSM was found in the model for ADCS-ADL 
(p=0.0108). Patients younger than 80 had a significantly higher partial correlation coefficient 
(ρ=0.33) between the SPSM score and ADCS-ADL than older subjects (ρ= −0.09). Similar 
to SPPB, spousal caregiver relationship had no impact on correlations between SPSM and 
ADCS-ADL.
Discussion
Obtaining reliable physical function assessments from cognitively impaired study subjects 
poses challenges in terms of subject’s ability to provide self-reports and the subject’s 
understanding and ability to perform physical tasks correctly.27 While there is no gold 
standard measure of physical function among older adults with AD, in the study section 
review of our ongoing clinical trial9 reviewers recommended that performance-based 
measures be collected rather than relying on proxy reports of physical function. Previous 
studies have used SPPB23,28–30 and SPSM24 as performance based measures in older adults, 
but not necessarily focused on older adults with dementia. The ADCS-ADL is a 
standardized measure and has been widely used in prior AD clinical trials but it relies on 
self-reports of caregivers rather than performance-based assessments.9,31–33 This study 
examines whether proxy reports are correlated with performance-based measures. We found 
significant correlations between caregiver-reports using the ADCS-ADL when compared to 
observed performance-based measures across all levels of cognitive function, with patients 
in the lowest cognitive group showing the highest correlation. These results also indicate that 
the SPPB and SPSM appear not to be significantly affected by impaired cognition and thus 
are reasonable performance-based physical function measures to include in trials targeting 
older adults with dementia. We also found that proxy reports are correlated with 
performance-based measures and thus could offer a lower cost, more practical measure of 
physical function in the context of clinical trials for AD.
A pilot study by Fox et al. examined the psychometric properties of certain functional and 
anthropometry measures including SPPB and grip strength among dementia patients living 
in residential aged care. While they found grip strength and anthropometric measures to be 
reliable in this population, other functional measures like the SPPB were found to have low 
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levels of absolute reliability and high variance at the individual level. Data on MMSE scores 
or level of dementia was not reported in that study.27 Bruce-Keller et al. demonstrated the 
complex interaction between cognitive function and physical performance, finding changes 
in individual cognitive domains to be more correlated than global cognitive measures, 
specifically in early changes to gait and SPPB in mildly demented patients.34 Building on 
these findings, this study incorporated correlations across the cognitive spectrum, taking into 
account MMSE of patients as well as caregiver-reported function and professionally-
observed patient performance. Notably, the SPPB had stronger correlations with ADCS-
ADL than SPSM. This finding may suggest that mobility and standing balance are more 
closely associated with function than lean mass and strength in patients such as those 
enrolled in this study.
Performance-based measures might be argued as ideal for assessing function in persons with 
AD, but these measures have important practical limitations. The SPPB is a well-established 
measure of lower body physical functioning that was shown to identify persons at greater 
risk for functional decline.24 The SPPB, in conjunction with the SPSM which combines 
muscle quantity and function 24, could be considered a well-balanced performance-based 
physical assessment. However, these scales were not specifically designed for assessment of 
persons with AD. Each assessment was completed in the patient’s home. This factor creates 
differences in assessment administration because each home environment is unique. 
Standardization is a challenge for items like chair rises, which require the patient to have a 
hard-surfaced, average height chair, and open wall space to use. Gait speed was occasionally 
administered with limited space, and moving furniture was sometimes necessary. It was 
sometimes difficult to create a comfortable and safe environment for movement and 
positioning during balancing. Environmental distractions during the testing such as 
interruptions by family members, televisions, or other media were additional obstacles for 
research staff
Administration of the ADCS-ADL posed its own set of practical limitations in data 
collection in the ADMIT trial. Caregivers varied in their understanding of the ADCS-ADL 
questions and additional explanation was often needed. The multiple choice answer 
selections from the ADCS-ADL required clarification, and sometimes none of the options fit 
the caregivers’ explanation. In these circumstances the caregiver would be prompted to 
choose the “best option.” Furthermore, ADCS-ADL questions tended to be catalysts for 
conversation and stories that caregivers wanted to share. Research assistants at times found it 
difficult to keep the interview on track while respecting additional information caregivers 
were willing to share.
The ADMIT data collection was able to incorporate a home-based evaluation-setting for 
both the patient assessments and caregiver reports. An important consideration when 
choosing this method over clinic or phone interviews is additional time and travel expenses. 
In-home assessments were typically completed in 40–70 minutes. Each home visit required 
an average of 14 miles of driving distance which equated to $8 in mileage reimbursement. 
An hour was typically allotted for each in-home assessment with 30–60 minutes of travel 
time in between those visits.
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Overall, our findings indicate that (a) caregiver-reports provide a reliable portrayal of how 
patients will perform on performance-based measures of physical function and cognition and 
(b) in this trial cohort, our two performance-based measures (SPPB and SPSM) appeared to 
be valid and not affected by the patient’s degree of cognitive impairment. In fact, the 
strongest correlation was shown in the lowest cognitive group. Going forward, these three 
outcome metrics (SPPB, SPSM, and ADCS-ADL) show to be acceptable measures for use 
in AD patients and the ADMIT trial.
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Figure 1. 
Scatter plots and univariate linear regression lines of the association of the performance-
based physical function measures with the ADCS-ADL score
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